Financial Performance - Net sales for Q3 2025 were $40.0 million, a 19.0% increase from $33.6 million in Q3 2024[1][9] - Operating income for Q3 2025 was $4.8 million, up 45.5% from $3.3 million in Q3 2024[1][9] - Net income for Q3 2025 was $4.2 million, or $0.34 per share, compared to $3.5 million, or $0.28 per share, in Q3 2024[1][9] - For the nine months ended September 30, 2025, net sales increased to $120.6 million from $107.5 million in the same period of 2024, representing a 12.9% growth[2][9] - Operating income for the first nine months of 2025 was $17.0 million, a 40.5% increase from $12.1 million in the same period of 2024[2][9] - Net income for the nine months ended September 30, 2025, was $14.8 million, or $1.20 per share, compared to $12.1 million, or $0.98 per share, in the same period of 2024[2][9] Sales Growth Drivers - The increase in net sales was attributed to higher sales in Security Products and Marine Components segments[3] Company Operations - CompX operates from three locations in the U.S. and employs approximately 558 people[4] Risks and Uncertainties - The company faces risks including supply chain disruptions, raw material cost fluctuations, and competition from low-cost manufacturers[6][7] - Future results may differ due to various uncertainties, including new product development and potential litigation[5][6]

Financial Performance - Net sales for the three and nine months ended September 30, 2025, were $1,273.7 million and $3,754.5 million, respectively, with a 2.7% increase and a 0.8% decrease compared to the same periods in 2024[193]. - In local currency, net sales increased by 3.2% and 1.5% for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024[193]. - Net income attributable to Herbalife for the three months ended September 30, 2025, was $43.2 million, or $0.42 per diluted share, reflecting an 8.9% decrease compared to the same period in 2024[195]. - For the nine months ended September 30, 2025, net income attributable to Herbalife was $142.9 million, or $1.38 per diluted share, representing an 87.0% increase compared to the same period in 2024[195]. - The 2.7% increase in net sales for the three months ended September 30, 2025, was primarily driven by a 3.5% favorable impact of price increases[193]. - The decrease in net income for the three months ended September 30, 2025, was mainly due to $10.6 million higher royalty overrides and $8.5 million higher income taxes[195]. - The increase in net income for the nine months ended September 30, 2025, was mainly due to $111.1 million lower selling, general, and administrative expenses[195]. Regional Performance - North America reported net sales of $263.1 million for the three months ended September 30, 2025, an increase of $2.7 million, or 1.0%, compared to the same period in 2024[214]. - Latin America experienced a 10.9% increase in net sales for the three months ended September 30, 2025, totaling $229.6 million compared to $207.1 million in 2024[209]. - Net sales in Mexico were $146.8 million for Q3 2025, reflecting an increase of $15.3 million or 11.6% compared to Q3 2024[219]. - EMEA region net sales reached $272.3 million for Q3 2025, an increase of $10.4 million or 4.0% compared to Q3 2024[222]. - Asia Pacific region (excluding China) reported net sales of $437.4 million for Q3 2025, a slight increase of $1.3 million or 0.3% compared to Q3 2024[225]. - India market net sales were $226.4 million for Q3 2025, an increase of $8.1 million or 3.7% compared to Q3 2024[226]. - Vietnam market net sales reached $71.5 million for Q3 2025, an increase of $1.8 million or 2.6% compared to Q3 2024[227]. - China region reported net sales of $71.3 million for Q3 2025, a decrease of $3.5 million or 4.7% compared to Q3 2024[229]. Cost and Expenses - Gross profit for the three months ended September 30, 2025, was $989.5 million, representing 77.7% of net sales, down from 78.3% in 2024[232]. - Selling, general, and administrative expenses for the three months ended September 30, 2025, were $447.6 million, or 35.1% of net sales, down from 35.8% in 2024[238]. - Income taxes for the three months ended September 30, 2025, were $31.7 million, with an effective tax rate of 42.4%, up from 32.9% in 2024[246]. - The gross profit margin for the three months ended September 30, 2025, was 77.7%, down from 78.3% in 2024, while for the nine months it was 78.0%, slightly up from 77.9% in 2024[202]. - Royalty overrides for the three months ended September 30, 2025, were $416.1 million, maintaining 32.7% of net sales, and for the nine months, they were $1,224.4 million, at 32.6% of net sales, consistent with 2024[236]. Strategic Initiatives - The company continues to focus on enhancing customer experience and expanding market penetration through initiatives like Nutrition Clubs and Fit Clubs[174]. - The company is focusing on enhancing technology tools, including digital start-up kits and E-commerce tools, to support Members in marketing and selling products[216]. - The company implemented a 2.3% price increase in January 2025 across most regions to support sales[216]. - The majority of markets in Latin America instituted price increases to address market-specific conditions during the nine months ended September 30, 2025[220]. - The beta version of the Pro2col health and wellness digital platform was unveiled in July 2025, with a commercial release planned for Q4 2025 in the U.S. and Puerto Rico[217]. Financial Management and Capital Expenditures - Operating cash flow for the nine months ended September 30, 2025, was $235.0 million, an increase from $215.8 million in 2024, driven by $101.8 million higher net income excluding non-cash items[249]. - Capital expenditures for the nine months ended September 30, 2025, were $61.0 million, down from $83.6 million in 2024, with a focus on management information systems and the $400 million Digital Technology Program[250]. - The company expects total capital expenditures of approximately $80 million to $90 million for the full year 2025, including investments in the Herbalife One initiative[250]. - The company acquired assets from Pruvit, Pro2col LLC, and Link BioSciences Inc. for approximately $25.5 million in 2025, with potential additional payments based on performance targets[251]. Debt and Financing - The company issued $800.0 million of senior secured notes due 2029 with an interest rate of 12.250% per annum, maturing on April 15, 2029[268]. - As of September 30, 2025, the outstanding principal on the 2029 Secured Notes was $800.0 million[268]. - The company repurchased $287.5 million and $65.5 million of its 2024 Convertible Notes in December 2022 and August 2023, respectively[270]. - The company repaid a total of $197.0 million on the 2024 Convertible Notes upon maturity in March 2024[270]. - The company issued $277.5 million of convertible senior notes due 2028, paying interest at 4.25% per annum, maturing on June 15, 2028[272]. - The company redeemed $300.0 million of the 2025 Notes for an aggregate purchase price of $309.1 million in April 2024[273]. - As of September 30, 2025, the company had working capital of $106.3 million, an increase of $193.0 million from negative working capital of $86.7 million as of December 31, 2024[282]. Tax and Regulatory Matters - The company accounted for uncertain tax positions under ASC 740, recognizing tax benefits only if it is more likely than not that the position will be sustained upon examination[298]. - The company has initiated changes to its corporate entity structure, including intra-entity transfers of intellectual property, which may affect future taxable income estimates[297]. - The company recognized a step-up in tax basis on the fair value of intellectual property due to changes in its corporate entity structure, requiring significant estimates and assumptions for valuation[297].

Financial Performance - Revenues for the third quarter of 2025 increased by 50.7% year-over-year to $103.4 million, compared to $68.6 million in the third quarter of 2024[9] - Net Loss for the third quarter of 2025 was $(41.2) million, an increase of $20.2 million from $(21.0) million in the same quarter of 2024[9] - Free Cash Flow for the third quarter of 2025 was $(27.8) million, compared to $(20.5) million for the third quarter of 2024[9] - Revenues for the three months ended September 30, 2025, were $103,432 thousand, a significant increase from $68,638 thousand in the same period of 2024, representing a growth of 50.6%[28] - Gross profit for the nine months ended September 30, 2025, was $6,787 thousand, down from $39,832 thousand in the same period of 2024, indicating a decline of 83.0%[28] - Net loss attributable to Redwire Corporation for the nine months ended September 30, 2025, was $141,079 thousand, compared to a loss of $47,146 thousand in the same period of 2024, representing a deterioration of 198.5%[28] - Free Cash Flow for the nine months ended September 30, 2025, was $(170,496) thousand, compared to $(31,264) thousand in the same period of 2024, indicating a negative change of 444.5%[40] Liquidity and Assets - Total liquidity as of September 30, 2025, was $89.3 million, up from $61.1 million in the third quarter of 2024[9] - Total current assets increased to $210,640,000 as of September 30, 2025, up from $125,925,000 on December 31, 2024, representing a 67% increase[26] - Cash, cash equivalents, and restricted cash rose to $54,328,000, compared to $49,071,000, indicating an increase of 7%[26] - Cash, cash equivalents, and restricted cash at the end of the period were $54,328 thousand, up from $43,094 thousand at the end of September 30, 2024, showing an increase of 26.3%[30] Liabilities and Equity - Total liabilities increased to $413,332,000 from $344,526,000, marking a rise of 20%[26] - Long-term debt net increased to $184,699,000 from $124,464,000, a 48% increase[26] - Shareholders' equity improved to $928,045,000 from a deficit of $188,714,000, indicating a substantial recovery[26] Operational Metrics - Gross Margin for the third quarter of 2025 was 16.3%, with an Adjusted Gross Margin of 27.1%[1] - Adjusted Gross Profit for the three months ended September 30, 2025, was $28,037 thousand, with an Adjusted Gross Margin of 27.1%, compared to 17.5% in the same period of 2024[38] - Operating expenses for the three months ended September 30, 2025, totaled $58,662 thousand, compared to $24,635 thousand in the same period of 2024, reflecting an increase of 138.0%[28] Book-to-Bill and Backlog - Book-to-Bill ratio improved to 1.25, with a Contracted Backlog of $355.6 million as of the third quarter of 2025[1][3] - The book-to-bill ratio for the three months ended September 30, 2025, was 1.25, compared to 0.65 for the same period in 2024[44] - The contracted backlog as of September 30, 2025, was $355.6 million, an increase from $296.7 million as of December 31, 2024[47] - Organic backlog at the end of September 30, 2025, was $279.5 million, down from $296.7 million at the end of December 31, 2024[47] - Acquisition-related backlog as of September 30, 2025, was $76.1 million, with $73.7 million of this value acquired during the period[47] Strategic Initiatives - The acquisition of Edge Autonomy is expected to drive revenue synergies and improve financial positioning[3] - The company launched 14 PIL-BOXes to the ISS during the third quarter of 2025 with three partners[2] - Positive demand signals are anticipated from both the U.S. and Europe for various products and solutions[3] Risks and Challenges - The company faces various risks including economic uncertainty, integration challenges from acquisitions, and reliance on government contracts[16] - The forecast for full-year revenues for 2025 is between $320 million and $340 million, impacted by the ongoing U.S. government shutdown[5]

Financial Performance - Revenue for Q3 2025 was $1.42 billion, up 31% from $1.08 billion in Q3 2024[4] - Net income attributable to the Company was $3.6 million, or EPS of $0.07, compared to a net loss of $100.9 million, or a loss per share of $1.92 in Q3 2024[7] - Adjusted EPS for Q3 2025 was $1.15, up from an adjusted loss per share of $1.61 in Q3 2024[9] - Gross profit for Q3 2025 was $169.40 million, compared to a loss of $25.83 million in Q3 2024, indicating a significant turnaround[39] - Total revenue for the nine months ended September 30, 2025, was $4,035.67 million, up from $3,259.27 million in the same period of 2024, reflecting a 24% increase[39] - The company reported a net income of $108,683 for the nine months ended September 30, 2025, compared to a net loss of $46,131 in the same period of 2024[49] Construction Operations - Income from construction operations was $40.1 million, a significant increase from a loss of $106.8 million in Q3 2024[6] - Tutor Perini Corporation's income from construction operations for Q3 2025 was $40.09 million, a recovery from a loss of $106.81 million in Q3 2024[39] - Income from construction operations for the nine months ended September 30, 2025, was $181,849, compared to a loss of $17,508 in the same period of 2024, indicating a significant turnaround[44] Cash Flow and Debt - Record operating cash flow of $289.1 million in Q3 2025, compared to $22.6 million in Q3 2024[10] - Total debt decreased by 23% to $413 million as of September 30, 2025, with cash exceeding total debt by $283 million[14] - Cash flows from operating activities for the nine months ended September 30, 2025, were $574,396, compared to $173,970 in 2024, reflecting a substantial increase of 230.5%[49] - Cash, cash equivalents, and restricted cash at the end of the period were $758,084, compared to $301,397 at the end of September 30, 2024, showing a significant increase[49] Backlog and Future Outlook - Backlog reached a record $21.6 billion, up 54% year-over-year, with $2.0 billion in new awards during Q3 2025[13] - The Company expects strong demand for construction services driven by well-funded infrastructure projects over the next several years[22] - Management anticipates significantly higher revenue and earnings in 2026 and 2027 as new large projects advance to the construction phase[19] - The backlog at September 30, 2025, was $21,640.8 million, compared to $18,673.9 million at December 31, 2024, indicating an increase of 15.8%[51] - The company recognized $7,002.6 million in revenue from new awards in the backlog for the nine months ended September 30, 2025[51] Capital Expenditures and Investments - Capital expenditures for Q3 2025 totaled $48.95 million, compared to $6.91 million in Q3 2024, indicating increased investment in operations[41] - Capital expenditures for the nine months ended September 30, 2025, totaled $105,891, significantly higher than $28,266 in the same period of 2024[49] Assets and Financial Position - Total current assets as of September 30, 2025, were $4,172,321, up from $3,286,667 as of December 31, 2024, marking an increase of 27%[47] - Total assets increased to $5,165,254 as of September 30, 2025, from $4,242,710 as of December 31, 2024, representing a growth of 21.8%[47] Risks and Challenges - The company highlighted ongoing risks including economic factors, litigation outcomes, and competition that could impact future performance[36]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 10-Q __________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39716 __________________________________ | Large accel ...

Financial Performance - Total revenue for Q3 2025 was $107.8 million, representing a 20% increase from $89.5 million in Q3 2024[4] - Net income for Q3 2025 was $89.9 million, or $1.30 per share, compared to $1.2 million, or $0.02 per share, in Q3 2024[8] - Total revenue for the three months ended September 30, 2025, was $107.8 million, a 20.5% increase from $89.5 million in the same period of 2024[15] - Net product sales reached $47.3 million for the three months ended September 30, 2025, compared to $27.8 million in the prior year, reflecting a 70% growth[15] - Gross profit for the three months ended September 30, 2025, was $75.5 million, up from $73.0 million in 2024, indicating a gross margin improvement[15] - Net income for the three months ended September 30, 2025, was $89.9 million, significantly higher than $1.2 million in the same period of 2024[15] Expenses and Cash Flow - Operating expenses increased to $41.0 million for the three months ended September 30, 2025, from $29.8 million in 2024, primarily due to higher research and development costs[15] - Cash and cash equivalents at the end of the period were $476.5 million, up from $260.6 million at the end of September 2024, representing an 83% increase[19] - The company reported net cash provided by operating activities of $142.4 million for the nine months ended September 30, 2025, compared to $129.5 million in 2024[19] Strategic Developments - The company announced a $125 million share repurchase program, highlighting confidence in its future prospects[3] - ZEVTERA was launched in the U.S. in July 2025, with initial market engagement focused on formulary committee and access programs[8] - Zoliflodacin is under Priority Review by the FDA, with a PDUFA target action date of December 15, 2025[8] - Innoviva invested $15.0 million in a term loan to Armata Pharmaceuticals, which recently reported positive Phase 2 data[12] - Innoviva acquired a proprietary long-acting oral drug delivery platform from Lyndra Therapeutics for $10.2 million, plus potential milestone payments[12] Asset and Equity Growth - The company's strategic assets were valued at $483.0 million as of September 30, 2025[7] - Total assets increased to $1.43 billion as of September 30, 2025, from $1.30 billion at the end of 2024, reflecting strong growth in the balance sheet[17] - The company’s equity increased to $1.01 billion as of September 30, 2025, compared to $691.2 million at the end of 2024, indicating a robust financial position[17] Research and Development - Research and development expenses surged to $13.7 million for the three months ended September 30, 2025, compared to $3.6 million in the same period of 2024, highlighting a focus on innovation[15]

Financial Performance - Net service revenue for Q3 2025 was $263.6 million, representing a 3.9% increase from $253.6 million in Q3 2024[4] - Adjusted EBITDA for Q3 2025 was $27.0 million, up 10.2% from $24.5 million in Q3 2024[4] - Net income attributable to Enhabit, Inc. was $11.1 million, a significant recovery from a net loss of $110.2 million in Q3 2024, marking a 110.1% improvement[5] - Operating income for Q3 2025 was $16.8 million, compared to an operating loss of $98.0 million in Q3 2024[20] - Net income attributable to Enhabit, Inc. for the nine months ended September 30, 2025, was $34.1 million, a significant recovery from a net loss of $110.2 million in the same period of 2024[20] - Adjusted EBITDA for the nine months ended September 30, 2025, was $80.5 million, up from $75.0 million in the same period of 2024[27] - Basic earnings per share for Q3 2025 was $0.22, recovering from a loss of $2.20 per share in Q3 2024[25] Revenue Growth - Hospice net service revenue reached $63.1 million, a 20.0% increase from $52.6 million in Q3 2024, with Adjusted EBITDA for hospice rising 72.0% year-over-year[10] - Home health average daily census (ADC) grew by 3.7% year-over-year, while hospice ADC increased by 12.6%[4] - Home health admissions grew by 3.6% year-over-year, with non-Medicare admissions increasing by 10.4%[4] - The updated guidance for 2025 projects net service revenue between $1,058 million and $1,063 million, with Adjusted EBITDA expected to be between $106 million and $109 million[11] Cash Flow and Debt Management - The company reported a net cash provided by operating activities of $66.3 million for the nine months ended September 30, 2025, compared to $55.3 million in 2024[24] - Cash and cash equivalents increased to $56.9 million as of September 30, 2025, compared to $28.4 million at the end of 2024[22] - The company reduced total bank debt by $100.0 million since Q4 2023, resulting in annualized cash interest savings of $19.2 million[7] - The net cash provided by operating activities for the nine months ended September 30, 2025, was $66.3 million, an increase from $55.3 million in 2024[33] Expenses and Margins - General and administrative expenses as a percentage of revenue remained stable at 38.1% for both Q3 2025 and Q3 2024[5] - General and administrative expenses as a percentage of revenue decreased to 40.0% in Q3 2025 from 40.9% in Q3 2024[35] - The gross margin as a percentage of revenue for the three months ended September 30, 2025, was 48.5%, compared to 48.1% in 2024[35] Strategic Developments - The company opened two new hospice de novo locations during the quarter[4] - The company anticipates continued growth opportunities despite potential risks related to regulatory changes and market conditions[36] - The company incurred $19.3 million in gains from the sale of investments during the nine months ended September 30, 2025[24] - The company plans to exclude the cash impact of unusual and nonrecurring items from future adjusted free cash flow calculations[33] Segment Performance - Total Segment Adjusted EBITDA for the nine months ended September 30, 2025, was $157.7 million, compared to $152.1 million in 2024[30] - Segment Adjusted EBITDA for the three months ended September 30, 2025, was $33.9 million, compared to $36.5 million in 2024, reflecting a margin of 16.9% versus 18.2%[30] - For the three months ended September 30, 2025, the company reported a net service revenue of $200.5 million, a slight decrease from $201.0 million in the same period of 2024[30] Unusual Items - The company incurred $2.0 million in unusual or nonrecurring items for the three months ended September 30, 2025, related to restructuring and legal fees[33]

Revenue Performance - Total revenue for Q3 2025 was $215.1 million, a 15% increase from $186.6 million in Q3 2024[6] - Freshworks reported Q3 2025 revenue of $215,118,000, a 15% increase from $186,575,000 in Q3 2024[27] - For Q4 2025, revenue is expected to be between $217.0 million and $220.0 million, reflecting a year-over-year growth of 12% to 13%[9] - Full year 2025 revenue guidance is raised to between $833.1 million and $836.1 million, indicating a 16% year-over-year growth[9] Profitability Metrics - Non-GAAP income from operations was $45.2 million, with a non-GAAP operating margin of 21.0%, compared to $24.0 million and 12.8% in Q3 2024[6] - Gross profit for Q3 2025 was $182,163,000, compared to $156,769,000 in Q3 2024, reflecting a gross margin improvement[27] - Non-GAAP net income for Q3 2025 was $46,776, compared to $33,573 in Q3 2024, representing a 39.2% increase[34] - GAAP gross margin for Q3 2025 was 84.7%, slightly up from 84.0% in Q3 2024[33] - Non-GAAP operating margin for Q3 2025 was 21.0%, compared to 12.8% in Q3 2024, showing a significant improvement[34] Cash Flow and Operating Activities - Net cash provided by operating activities was $63.5 million, representing an operating cash flow margin of 29.5%, up from $42.3 million and 22.7% in Q3 2024[6] - The company reported a net cash provided by operating activities of $63,472,000 for Q3 2025, up from $42,329,000 in Q3 2024[31] - Adjusted free cash flow was $57.2 million, with an adjusted free cash flow margin of 26.6%, compared to $40.1 million and 21.5% in Q3 2024[6] - Adjusted free cash flow for Q3 2025 was $57,209, compared to $40,105 in Q3 2024, marking a 42.6% increase[35] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $180,036, up from $119,284 in the same period of 2024, a 51.0% increase[35] Customer Metrics - The number of customers contributing more than $5,000 in ARR increased by 9% year-over-year to 24,377[11] - The net dollar retention rate was 105%, slightly down from 107% in Q3 2024[11] Cost Management - Operating expenses totaled $189,620,000 in Q3 2025, down from $195,633,000 in Q3 2024, indicating cost management efforts[27] - Stock-based compensation expense for Q3 2025 was $48,529,000, down from $58,709,000 in Q3 2024[32] Asset and Liability Overview - Cash and cash equivalents decreased to $420,934,000 as of September 30, 2025, from $620,315,000 at the end of 2024[29] - Total assets decreased to $1,371,959,000 as of September 30, 2025, down from $1,611,884,000 at the end of 2024[29] - Deferred revenue increased to $348,001,000 as of September 30, 2025, compared to $323,435,000 at the end of 2024, indicating strong future revenue potential[29] Management Changes - The company appointed Enrique Ortegon as Senior Vice President and General Manager of Americas Field Sales[11] Currency Impact - Freshworks' revenue adjusted for constant currency also showed a 15% growth, indicating stable performance despite currency fluctuations[32]

– Achieved Record Quarterly Revenues and Net Income from Water Segment Exhibit 99.1 TEXAS PACIFIC LAND CORPORATION ANNOUNCES THIRD QUARTER RESULTS – Earnings Call to be Held Thursday, November 6, 2025 at 9:30 am CT DALLAS, TX (November 5, 2025) – Texas Pacific Land Corporation (NYSE: TPL) (the "Company," "TPL," "we," "our" or "us"), one of the largest landowners in the State of Texas with surface and royalty ownership that provides revenue opportunities through the support of energy production, today announ ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Nick Nottoli Allister Gobin Media Relations Investor Relations mediateam@allstate.com (847) 402-2800 Allstate Reports Third Quarter 2025 Results Transformative Growth execution results in strong operating results NORTHBROOK, Ill., November 5, 2025 – The Allstate Corporation (NYSE: ALL) today reported financial results for the third quarter of 2025. "Allstate delivered excellent operating results in the third quarter," said Tom Wilson, who leads The Allstate Corpo ...